The intriguing roles of Siglec family members in the tumor microenvironment
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Sialic acid-binding receptors are expressed on the surfaces of a variety of immune cells and have complex and diverse immunoregulatory functions in health and diseases. Recent studies have shown that Siglecs could play diverse immune and nonimmune regulatory roles in the tumor microenvironment (TME) and participate in tumor progression through various mechanisms, such as regulating tumor growth and metastasis, mediating the inflammatory response, and promoting tumor immune escape, thereby affecting the prognoses and outcomes of patients. However, depending on the cell type in which they are expressed, each Siglec member binds to corresponding ligands in the microenvironment milieu to drive diverse cell physiological and pathological processes in tumors. Therefore, we herein summarize the expression spectra and functions of the Siglec family in human diseases, particularly cancer, and highlight the possibility of therapeutic interventions targeting the TME in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TME also promotes abnormal sialylation in tumor cells and modulates the expression of siglec on infiltrating immune cells [268].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [268]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Studies have shown that a single-agent checkpoint blockade (anti-PD-L1/PD-1) is rarely effective in some subgroups [71].”
BackgroundSingle-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors
Villani, A.-C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J., Griesbeck, M., Butler, A., Zheng, S., Lazo, S., et al. (2017) · Science · doi:10.1126/science.aah4573 · Cited by 2,413 · cited 7×
“Abbreviations TME: Tumor microenvironment; DCs: Dendritic cells; NK cells: Natural killer cells; Sia: Sialic acid; DAMPs: Damage associated molecular patterns; ITAM: Immunoreceptor tyrosine‑based activation motif; ITIM: Immunoreceptor tyrosine‑based inhibition motif; SHPs: SH2 domain‑containing protein tyrosine phosph…”
BackgroundInfluentialSiglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031 · cited 5×
“Inhibitory Siglecs include Siglec-3, Siglec-5, Siglec-7, Siglec-9, and Siglec-10, and their intracellular regions contain ITIM- and ITIM-like domains, which transduce inhibitory signals by recruiting tyrosine phosphatases (SH2 domain-containing protein tyrosine phosphatases, SHPs), such as SHP-1 and SHP-2 [8, 9].”
BackgroundInfluentialCD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385 · cited 2×
“This negatively regulates intracellular signaling, inhibits phagocytosis by macrophages and promotes tumor immune escape [37].”
BackgroundSiglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122 · cited 1×
“Human Siglec-4, Siglec-14, Siglec-15, Siglec-16 and mouse Siglec-H belong to this classification [8, 10].”
BackgroundSiglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Wang, J., Sun, J., Liu, L. N., Flies, D. B., Nie, X., Toki, M., Zhang, J., Song, C., Zarr, M., Zhou, X., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0374-x · Cited by 679 · cited 1×
“[57] demonstrated that the upregulation of Siglec-15 expression in some tumor cells inhibited CD8+ T-cell proliferation and activation in vitro and in vivo in Siglec-15-deficient mice.”
BackgroundMuch More than M1 and M2 Macrophages, There are also CD169+ and TCR+ Macrophages
Chávez-Galán, L., Olleros, M. L., Vesin, D., & Garcia, I. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00263 · Cited by 653 · cited 1×
“The Leslie Chávez-Galán team also defined TCR +Siglec-1+ macrophages as another macrophage subgroup in the TME that can potentially serve as another clinical treatment target in diseases other than cancer [17].”
BackgroundSiglecs as Immune Cell Checkpoints in Disease
Duan, S., & Paulson, J. C. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-102419-035900 · Cited by 452 · cited 1×
“The intracellular domain is divided into a short lysine-containing tail and an extracellular structural domain consisting of an N-terminal binding Ig domain and a variable number of C2-type structural domains [6].”
BackgroundJandus, C., Boligan, K. F., Chijioke, O., Liu, H., Dahlhaus, M., Démoulins, T., Schneider, C., Wehrli, M., Hunger, R. E., Baerlocher, G. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65899 · Cited by 439 · cited 2×
“Moreover, Siglec-9+ NK cells highly express the chemokine receptors CXCR1 and CX3CR1 and can recruit IL-8 to promote tumor proliferation, invasion, and neovascularization [26].”
BackgroundBeatson, R., Tajadura-Ortega, V., Achkova, D., Picco, G., Tsourouktsoglou, T.-D., Klausing, S., Hillier, M., Maher, J., Noll, T., Crocker, P. R., et al. (2016) · Nature Immunology · doi:10.1038/ni.3552 · Cited by 378 · cited 15×
“Although the relationship between the expression of Siglecs and PD-L1 in the TME is not clear, anti-PD-1 and anti-Siglec therapies in combination might have improved efficacy.”
BackgroundInfluential
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Wen, R. M., Stark, J. C., Marti, G. E., Fan, Z., Lyu, A., Garcia-Marques, F. J., Zhang, X., Riley, N. M., Totten, S. M., Bermudez, A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180282 · Cited by 69
Jangid, A. K., Kim, S. J., & Kim, K. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00404-8 · Cited by 40
Sialic acid and Siglec receptors in tumor immunity and immunotherapy
Mantuano, N. R., & Laubli, H. P. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101893 · Cited by 50
Wu, Y., Ai, H., Xi, Y., Tan, J., Qu, Y., Xu, J., Luo, F., & Dou, C. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101165 · Cited by 55
Metadata
- Authors
- Jiang, K.-Y., Qi, L.-L., Kang, F.-B., & Wang, L.
- Affiliations
- Third Hospital of Hebei Medical University (CN)
- Corresponding author
- Wang, Ling
- ORCID
- Wang, Ling
- Venue
- Biomarker Research
- Published
- 2022-04-13
- Volume
- 10
- Issue
- 1
- Pages
- 22-22
- ISSN
- 2050-7771 (ISSN-L)
- PMC
- PMC9008986
- OpenAlex
- W4223999372
- Cited by
- 43
- References
- 87
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 13 · 2023: 14 · 2022: 2
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Biomarker Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82173210)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- sialic acid-binding lectins, tumor microenvironment, tumor immunology, tumor immune evasion, metastasis, tumor inflammation, tumor progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The intriguing roles of Siglec family members in the tumor microenvironment. https://app.cochat.ai/papers/10.1186/s40364-022-00369-1
- The paper
- Jiang, K.-Y., Qi, L.-L., Kang, F.-B., & Wang, L. (2022). The intriguing roles of Siglec family members in the tumor microenvironment. Biomarker Research. https://doi.org/10.1186/s40364-022-00369-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.